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Background: An in silico mechanism-of-action analysis protocol was developed, 
comprising molecule bioactivity profiling, annotation of predicted targets with 
pathways and calculation of enrichment factors to highlight targets and pathways 
more likely to be implicated in the studied phenotype. Results: The method was 
applied to a cytotoxicity phenotypic endpoint, with enriched targets/pathways found 
to be statistically significant when compared with 100 random datasets. Application 
on a smaller apoptotic set (10 molecules) did not allowed to obtain statistically relevant 
results, suggesting that the protocol requires modification such as analysis of the most 
frequently predicted targets/annotated pathways. Conclusion: Pathway annotations 
improved the mechanism-of-action information gained by target prediction alone, 
allowing a better interpretation of the predictions and providing better mapping of 
targets onto pathways.
Drug discovery research has changed dra-
matically during its history. Traditionally, it 
was focused on phenotypic readouts: in this 
kind of experiments compounds are tested 
on organisms, tissues or cells showing a par-
ticular phenotype [1]. The development of the 
‘magic bullet’ theory by Ehrlich [2], which 
suggests as a goal the development of a drug 
that is highly selective against a particular tar-
get for a given disease, and more recently the 
advent of the genomic era have led to a shift 
away from phenotypic approaches and toward 
target-based approaches. Shortcomings are 
present in both phenotypic and target-based 
methodologies: the former by its nature 
neglects information on the biological targets 
of the tested compounds [3], since only the 
final response caused by a molecule adminis-
tration is observed. On the other hand, in the 
latter, efficacy of compounds can often not 
be sufficiently established until later clinical 
stages, since a number of important factors, 
such as the full bioactivity profile of a com-
pound and its ADMET/DMPK (absorption, 
distribution, metabolism, elimination and 
toxicity/drug metabolism and pharmacoki-
netics) properties are not taken into account 
early on. Hence, both approaches are affected 
by a lack of information about compound 
action, which may relate both to efficacy and 
toxicity. This lack of information represents 
one of the reasons why drugs often fail dur-
ing early clinical trials, a key problem for the 
current state of pharmaceutical industry [4,5]. 
Recently, phenotypic assays have experienced 
a resurgence [1,6], in parallel with a movement 
from the ‘one drug–one disease’ approach 
to considering the full polypharmacology of 
compounds [7–10]. This is due to several rea-
sons, primarily the lack of efficacy of modu-
lating single targets in many disease areas 
(although also exceptions, such as infectious 
diseases, exist). The importance of multi-
target activity is well established, for example, 
in CNS-related diseases such as mood disor-
ders and psychiatric diseases, where modula-
tion of multiple G-protein-coupled receptors 
(GPCRs) is of crucial importance [11]. Pheno-
typic readouts are now able to take the full 
bioactivity profile of compounds into account 
by their very nature, given that a large num-
ber of targets which may or may not be modu-
lated are also present in the assay, and their 
modulation is (or rather should be in case of 
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relevance) also be present in the readouts. However, one 
of the shortcomings of phenotypic assays is the lack of 
information about the precise mechanism of action 
(MoA) of a compound. In this context, chemoge-
nomics has recently been of increasing interest, where 
it is able to contribute by giving new insights into the 
MoA [12–16] as well as polypharmacological properties 
of a molecule [17], thus in addition allowing for drug 
repositioning [9,18–21], as well as a better understanding 
of compound side effects [22–26]. In particular, in silico 
target prediction methods appear to be important 
in filling in the gaps present in chemical bioactivity 
libraries, which are biased toward a limited number 
of therapeutically relevant protein targets and do not 
report the complete bioactivity spectrum of mole-
cules [27]. However, the lack of a complete knowledge 
regarding bioactivity of compounds represents also a 
limitation of in silico bioactivity deconvolution meth-
odologies. Since target prediction is based on the data 
available, predicting bioactivity spectra is limited by the 
ability of the training set to cover both chemical and 
biological space. Hence, despite their successes in the 
recent past, in silico bioactivity prediction approaches 
are still presented with some shortcomings that need 
to be addressed. For example, public data sources can 
be affected by a number of errors, spanning from the 
molecular structure to physicochemical properties and 
the accompanying biological annotations [28]. Thus, the 
reliability of the data sources used needs to be considered 
when evaluating the output of an algorithm, in combi-
nation with the completeness of chemical and biological 
space covered by the data [29]. Moreover, another severe 
shortcoming is that current in silico bioactivity profil-
ing tools do not consider the pharmacokinetics/phar-
macodynamics (PK/PD) properties of compounds [30], 
but rather assume that molecules are able to reach and 
interact with all proteins. Thus, they convert biologi-
cal responses that depend to a large extent on time and 
dose, to simplified, binary ‘yes/no’ decisions about the 
interaction of a compound with a target.
Furthermore, a number of ‘systems biology’ fac-
tors need to be considered when trying to understand 
the MoA of a compound better. As shown in Figure 1 
(green text), it is fundamental to take into account the 
chemical structure of the compound studied, the 
protein(s) it interacts with, as well as the complete net-
work of interacting proteins which can then be linked 
to the phenotypic response (instead of the protein tar-
get itself, which only represents one player along a chain 
of events). Such a ‘systems biology’ approach would fill 
the gap between chemistry and biology, thus potentially 
helping the drug discovery process in the future [31,32].
We will now summarize current approaches to 
in silico MoA analysis which consider analyses of 
chemical space, target space and phenotypic readouts, 
before making a case for using pathway annotations 
to improve MoA analyses and presenting our results 
in this area.
A recent application of in silico target predictions to 
in vitro and in vivo readouts was performed on pheno-
typic observations from a zebrafish behavioral model 
[33]. In this study, 681 molecules were selected for their 
ability to cause characteristic movements in response 
to a series of light stimuli (a photomotor response). 
The Similarity Ensemble Approach [34] was then 
applied to predict protein targets, and the novel mol-
ecule–protein pairs obtained were selected for in vitro 
affinity measurement. Eleven compounds, out of the 
20 tested, showed activity on 22 of the 31 predicted 
targets. Further validation of the implication of these 
targets in the phenotype comes from the comparable 
photomotor response profile observed for a set of 
chemically diverse ligands, which were still interacting 
with the same protein targets. Thus, the combination 
of target prediction with target-based as well as phe-
notypic readouts allowed the elucidation of the MoA 
of the tested compounds. The same target prediction 
method, Similarity Ensemble Approach, has also been 
used in what is probably the largest prospective valida-
tion of in silico target prediction methods. In this case, 
Key terms
Mechanism of action: Biological response derived from a 
drug administration, due to the interaction of the molecule 
with specific protein targets. It defines the functional 
changes on a molecular level, in contrast with ‘mode of 
action’, which instead refers to the changes observed after 
administration of a substance on a cellular level.
Chemogenomics: Discipline studying the interaction 
between small molecules and protein targets on a large 
scale (i.e., considering the activity of multiple ligands 
against multiple targets at once, as opposed to considering 
only individual ligand–target interactions).
Target prediction: In silico pattern recognition techniques 
used to infer small molecule–protein interaction by utilizing 
known bioactivity data of ligands.
Systems biology: Interdisciplinary (biological, 
mathematical, analytical, etc.) approach that derives 
from the recognized complexity of living organisms, 
whose behavior can be fully understood only through 
consideration of all the dynamic interactions between 
components of the biological system.
Cytotoxicity: Effects exerted by an agent (either molecules 
or other cells, such as lymphocytes) that leads to cellular 
damage and/or death through a mechanism of necrosis or 
apoptosis.
Apoptosis: Organized process of programmed cell death. 
In contrast to necrosis, which is the result of acute cell 
damage and affects neighbor cells, apoptosis does not 
affect negatively the surrounding tissue.
Figure 1. Chemical space (chemical structure of a drug), 
protein space (proteins: the drug targets) and the 
phenotypic readout space (symbolized by a human 
organism) are interconnected and cannot be considered 
as independent units. The lack of complete information 
present in each of the three data sources makes the links 
between them more important: the protocol presented 
here aims to integrate the information coming from the 
three vertexes, helping to draw the edges of the triangle. 
MoA: Mechanism of action. 
Reproduced with permission from [22] John Wiley and 
Sons © (2014). 
For color images please see online www.future-science.
com/doi/full/10.4155/FMC.14.137
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predictions were combined with side-effect informa-
tion on a set 656 US FDA approved drugs, with the 
aim to elucidate the underlying mechanism of side 
effects [24]. PK/PD properties of the compound–tar-
get–side effect triplets were manually checked to retain 
only the ones containing compounds likely to reach 
and interact with the target. This study was able to 
elucidate the biological mechanism underlying several 
side effects, such as the relationship between abdomi-
nal pain observed after treatment with the synthetic 
estrogen chlorotrianisene, which could be linked to the 
inhibition of cyclooxygenase–1 (PTGS1). This study 
hence demonstrates that also high-level in vivo read-
outs can be analyzed in silico; however, care needs to be 
taken also of other compound properties such as their 
PK/PD profiles. The above studies do not consider 
information about the underlying biological network 
though when analyzing in silico MoA predictions, and 
relatively few studies exist in this area as of now. One of 
the few applications of a network-based approach com-
prises the integration of a set of proteins known to be 
targeted by protoxins, their partners in protein–protein 
interaction and the pathways and biological processes 
in which these proteins are implicated [35]. The annota-
tion of these proteins with gene ontology (GO) terms 
followed by subsequent enrichment calculations found 
a limited number of biological processes significantly 
enriched as well as strongly implicated in the toxicity 
phenotype (such as pathways related to protein fold-
ing, immune system regulation and the MAP kinase 
signaling pathway). Overall, this study shows how 
the analysis of the targets together with the proteins 
with which they interact leads to greater insights into 
the mechanism of toxicity than by considering targets 
alone, both from the statistical and interpretability 
point of view – here 186 proteins could be summarized 
by a much smaller number of biological processes as 
annotated in GO. In a similar way, annotation of path-
ways to the known targets of a set of 16 FDA approved 
drugs helped in better elucidating their MoA [36]. In 
particular, 11 drugs were associated with enriched 
pathways relevant for their therapeutic effects. More-
over, pathways implicated in different diseases, which 
could be explored for drug repositioning, were found 
to be enriched for four of these drugs. An example is 
represented by celecoxib, inhibitor of prostaglandin-
endoperoxide synthase 2 (COX2): apart from arachi-
donic acid metabolism and eicosanoid synthesis, the 
list of enriched pathways for this drug included several 
cancer-related pathways whose activation by celecoxib 
was reported in previous experimental studies. Hence, 
the integration of pathway information appears to be a 
viable avenue to improve MoA elucidation studies, as 
well as to identify new therapeutic effects of molecules.
Please note that no in silico target prediction was part 
of the two studies described above; however, the sub-
sequent pathway analysis is similar to what we suggest 
in our work, namely, a combination of both of those 
parts, in silico target predictions, followed by pathway 
annotation of the predictions. Integration of pathway 
information combined to in silico bioactivity profiling 
was performed by Scheiber et al. [37], demonstrating 
how such approaches can help to obtain new insights 
into the side effects of compounds. A computational 
pipeline was developed to infer protein targets for a 
set of molecules responsible for the same side effect, 
and annotate them with pathways. Application of this 
pipeline to several datasets allowed the creation of 
links between side effects and perturbed pathways, as 
exemplified in the hypotension dataset by the estrogen 
receptor activation pathway.
In this study, we aim to now describe and validate the 
integration of in silico target prediction methods with 
subsequent pathways analysis, and to underline the 
value of integrating both approaches. This will be per-
formed on two sets of compounds which led to cyto-
toxicity and apoptosis in cell-based screenings, and 
therefore not influenced by compound PK/PD proper-
ties (as would be the case in more complex biological 
Figure 2. Pipeline of the developed protocol. (A) In silico bioactivity prediction is performed on a dataset of 
small molecules sharing the same phenotype. (B) The predicted targets are then annotated with the biological 
pathways where they are expressed, and finally (C) enrichment calculation is performed on both targets and 
pathways to select the ones statistically more relevant to the phenotype of study to subject to further analysis.
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systems, such as full organisms). The two datasets have 
additionally been chosen because of the importance of 
cytotoxicity, and more specifically apoptosis, in cancer 
therapeutics. (Tumor cells usually rely on glycolytic 
energy metabolism instead on mitochondrial oxidative 
metabolism [38], which allows them to escape the death 
control usually mediated by the mitochondria [39]. 
Chemotherapeutic agents should ideally act through 
apoptosis in order to specifically kill tumor cells and 
avoid the surrounding tissue damage that would follow 
a necrotic process.) To achieve this aim, the integration 
of in silico target predictions with automated pathway 
annotations [16] is used to obtain improved informa-
tion regarding the MoA of molecules responsible for 
the cytotoxicity and apoptosis phenotypes (Figure 1, 
red text). An in silico protocol was developed (shown 
in Figure 2), comprising the first step in bioactivity 
profile prediction (performed using a Laplacian-mod-
ified Naïve Bayes classifier described by Koutsoukas et 
al. [40]) for a dataset of molecules responsible for the 
same phenotypic response. The predicted protein tar-
gets were then annotated with the biological path-
ways they belong to according to KEGG [41], GO [42] 
and GO Slim [43] annotations. Subsequently, statistical 
measures such as enrichment factors were calculated to 
highlight targets and pathways most likely to be impli-
cated in the phenotype studied. Finally, the results 
obtained for the cytotoxic dataset were compared with 
100 random sets to understand whether integration of 
pathway information and enrichment calculation on 
a phenotypic dataset could give more relevant results 
than on random sets.
Materials & methods  
Experimental methods  
Apoptotic dataset
Twenty-two compounds were selected from the Prest-
wick Chemical Library [44] because of their activ-
ity in killing embryonic mouse stem cells detected 
Key term
Biological pathway: Set of interactions amongst proteins 
and molecules which leads to a particular cellular, tissue, 
organ or organism response
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by a colorimetric assay based on metabolic activity 
performed with the Cell Proliferation Kit II (XTT, 
Roche), as reported by Conesa et al. [45]. These com-
pounds were then used to treat HeLa cells in culture 
in order to determine if they could induce cell death 
in these tumor cells. Time lapse fluorescence micros-
copy was used to characterize the type of cell death 
and differentiate between apoptosis and necrosis (Leica 
DMI6000B inverted microscope and MetaMorph 
software). Cells were cultured in Dulbecco’s modified 
Eagle’s medium, supplemented with 10% fetal bovine 
serum, 2 mM glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin (all reagents from Invitrogen) a 
37ºC in 5% CO
2
 atmosphere. Nuclei and mitochon-
dria were stained by incubating the cells with 250 nM 
Hoechst 33342 (Invitrogen) and with MitoTracker 
Green FM (Invitrogen) at 250 nM, respectively, for 30 
min in cultured media. The media was then replaced 
with fresh media, and a 10 μM final concentration of 
each compound was added; one compound per well. 
Camptothecin was used as a positive control for apop-
tosis and DMSO, at 10 μM final concentration, as 
negative control. Images were acquired every 30 min 
for 24 h. Three images were acquired at 200× magnifi-
cation at each time point, using fluorescence filter sets 
for Hoechst and for MitoTracker Green, and bright 
field. The three images at each time point were then 
combined to build a composite image and images from 
all time points were assembled in a video using Meta-
Morph software. Cells with shrunk or fragmented 
nuclei, compacted mitochondria and membrane bleb-
bing, without release of cytosolic content, were consid-
ered apoptotic. Ten compounds were clearly inducing 
apoptotic cell death, and they were therefore selected 
for further computational analysis.
Cytotoxic dataset
1094 cytotoxic compounds were extracted from Pub-
Chem by selecting 186 bioassays describing molecules 
which had proved cytotoxic to HeLa cells in cell-based 
assays (Supplementary Table S10) as described by Cor-
tes-Ciriano et al. [46]. The targets of these compounds 
were predicted by the same Laplacian-modified Naïve 
Bayes classifier [40] used on this work. However, in Cor-
tes-Ciriano et al. the classifier was trained on a dataset 
extracted from ChEMBL version 10 [47] composed of 
105,946 compounds and covering 894 human targets. 
Other differences in the methodology consist in the 
score cutoffs and enrichment calculation (please refer 
to the following section ‘Computational Methods’ for 
details on the method used here). In the work of Cor-
tes-Ciriano, the predicted targets likely to interact with 
a compound were selected applying a general score cut-
off of 35, and only the top 15 targets were retained 
and considered enriched. The authors hypothesized 
that targets enriched from the ones generated by the 
target prediction algorithm were likely to be mecha-
nistically implicated in cytotoxicity. To validate the 
hypothesis, the same algorithm was applied to the Hit-
Finder chemical library [48]. Ten compounds exhibit-
ing high scores for two targets previously identified 
as implicated in cytotoxicity, P-glycoprotein 1 and 
Topoisomerase I, were prospectively tested to validate 
or invalidate the hypothesis. The screening led to iden-
tify five moderate inhibitors of Topoisomerase I and 
two inhibitors of PGP 1, confirming the implication of 
these targets in cytotoxicity. Given the available results 
obtained by Cortes-Ciriano et al., we decided to use 
this library to explore pathway annotations on this 
established dataset.
Computational methods 
Compound preprocessing
A pipeline to standardize the datasets was built using 
KNIME 2.7.4 [49] comprising MOE extensions for 
KNIME v2.1.8 [50] nodes. The procedure consisted 
of conversion of structures in 2D (using the node 
‘SMILES to Molecules’) salts stripping and molecules 
neutralization (‘Wash’), aromaticity and tautomerism 
canonicalization and duplicate removal (both steps 
performed with the ‘Filter Duplicates’ node).
Target prediction
In silico bioactivity profiles for the compounds were gen-
erated using the Laplacian-modified Naïve Bayes clas-
sifier described by Koutsoukas et al. [40]. Molprint2D 
[51] circular fingerprints of depth 3 were then generated 
using the OpenBabel [52]. The training set consists of 
189,147 ligand–protein pairs extracted from ChEMBL 
version 14 covering 477 human protein targets [16]. The 
model outputs a confidence score for each target (class) 
on a per-compound basis. Class-specific score cutoffs 
were derived by calculating the optimal balanced accu-
racy (precision and recall trade-off) on a per target class 
basis, and were used to retain protein targets likely to 
interact with the compounds in the dataset [16].
Pathway annotation
Protein-pathway annotations were extracted from three 
different sources, namely, KEGG [41] (release 58.1), 
GO biological processes [42] (extracted from UniProt 
2012_01 on 25 January 2012) and GO Slim biological 
processes [42] (retrieved using the QuickGO [43] appli-
cation on 15 October 2012). Different sources were 
used in parallel to overcome the lack of comprehensive 
information contained in databases [28–29,53–57], which 
arises from the different definition of KEGG pathways 
and GO biological processes. More specifically, KEGG 
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pathways are defined as molecular interaction/reaction 
network diagram including genes, proteins, RNAs, 
chemical compounds, glycans, chemical reactions, dis-
ease genes and drug targets. On the other hand, GO 
biological processes are strictly linked to genes, and 
represent a recognized series of events or molecular 
functions with a defined beginning and end, whose 
alteration can lead to a variation of the phenotype.
It was possible to annotate 405 out of 477 targets 
with 176 KEGG pathways, while all targets were anno-
tated with 2785 GO biological processes and 173 GO 
Slim biological processes.
Enrichment calculation
Enrichment calculation was performed to avoid over- 
and under-predictions/annotations to the extent pos-
sible, which could derive from biases in the data used. 
To this end, a background distribution was assembled 
in order to create a diverse library of compounds cover-
ing large chemical space. Approved drugs from Drug-
Bank, drug-like molecules from PubChem [58], human 
metabolites from HDMB [59], natural products from 
ZINC [60] and computationally generated compounds 
from GDB13 [61] were randomly sampled, yielding 
194,849 molecules with a molecular weight ranging 
from 100 to 900. The background distribution was 
subjected to compound preprocessing and target pre-
diction to obtain a final dataset of 194,433 molecules.
The Odds Ratio for a given target/pathway is cal-
culated by comparing the frequency of prediction/
annotation in the test set (F
t
) and the frequency of 
prediction/annotation in the background distribution 
(F
b
), taking into consideration the total number of 
predictions/annotations in each set (N).
Odds Ratio F
N
F
N
b
b
t
t=
Equation 1
The Average Ratio is similar to the Odds Ratio, but 
on a larger scale since 10,000 (n) datasets are used for 
the calculation. These datasets have the same number 
of compounds of the test set, and they are randomly 
generated from the background distribution. The 
Average Ratio for a given target/pathway is then calcu-
lated by comparing the frequency of prediction/anno-
tation in each random dataset (R
i
) with the frequency 
of prediction/annotation in the test dataset:
Average Ratio
i 1
n
n
1
F
R
t
i=
=
∑
Equation 2
The Estimation Score value describes the fraction 
of random samples whose frequency for a given tar-
get/pathway is above the observed one. It is calcu-
lated by counting how many times the frequency of 
prediction/annotation for target/pathway in the afore-
mentioned random datasets is higher or equal to the one 
in the test dataset (R
i
≥F
t
).  The absolute frequency (C) 
obtained is then divided by the total number of random 
dataset n yielding a value between 0 and 1.
n
c
Estimation score =
Equation 3
The Estimation Score is the first method used to rank 
targets and pathways according to their enrichment, 
and it estimates the statistical relevance of predicted 
targets or annotated pathways, respectively. More spe-
cifically, if the Estimation Score for a given target equals 
1, its frequency of prediction in the random datasets 
was always found to be higher than the one observed in 
the test set (and hence it is not found to be significant). 
Vice versa, if a target presents an Estimation Score of 
0, its frequency of prediction in the random datasets 
was never found to be higher than the one observed 
in the test set (and hence it is statistically significant; 
the same applies to pathways as well). Hence, if the 
Estimation Score equals 1 it is likely that the high 
frequency of encountering the target/pathway was a 
chance event, whereas a value close to 0 suggests a sta-
tistically significant target/pathway to be further ana-
lyzed and to be explored with respect to its potential 
biological meaning. In our case, targets and pathways 
with Estimation Score ≤ 0.01 are considered enriched. 
In case of targets/pathways having the same Estimation 
Score, the two other methods can be indistinctly used 
to discriminate between them, given their correlation 
(see Supplementary Information, Enrichment meth-
ods comparison). Please note that interpretation of 
the Estimation Score is purely probabilistic, not causal: 
meaningfulness of the results ultimately needs to be 
experimentally validated.
Data visualization
A total of 100 random datasets containing the same 
number of molecules as the cytotoxicity set were 
extracted from the background distribution using an 
in-house script. They were subjected to the computa-
tional pipeline previously described, and the average 
number of enriched items per class (targets, KEGG 
pathways, GO and GO Slim biological processes) was 
plotted for the random sets and the cytotoxicity set.
Compound-structure, compound-target and com-
pound-pathway binary matrices were generated by 
linking all compounds with the fingerprint features 
used to describe them, the targets they are predicted 
to interact with and the pathways they are annotated 
with. These matrices were used to construct distance 
matrices based on the binary method implemented 
in R [62]. For both binary and distance matrices the 
www.future-science.com 2035future science group
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heatmap 2 function of the ggplot package was used, 
where the complete linkage method was selected to 
perform hierarchical clustering.
Results & discussion 
Cytotoxicity dataset
A library of 1094 compounds cytotoxic for HeLa cells 
was subjected to the protocol outlined in detail in the 
Materials & Methods section. The dataset was chosen 
due to its number of data points, which allows statis-
tically significant results to be obtained, as well the 
readout being relatively free from PK/PD and other 
parameters (at least compared with many other, more 
complex phenotypic readouts). Out of 1094 com-
pounds, 948 successfully passed the standardization 
protocol, leading to a total of 400 unique predicted 
targets annotated with 172 unique KEGG pathways, 
2565 unique GO biological processes and 168 unique 
GO Slim biological processes. Enriched targets and 
pathways will be discussed and linked to the phenotype 
being studied in the next paragraphs.
Target analysis
The enrichment calculation for 400 predicted targets 
yielded 151 proteins statistically associated with the 
cytotoxic phenotype (Estimation Score ≤ 0.01), out 
of which for 110 the Estimation Score equals 0 (see 
Supplementary Table S1 for details). The considerable 
number of enriched targets is likely due to a combina-
tion of the size of the dataset as well as different MoAs 
involved in the cytotoxicity phenotype. Cytotoxicity 
can indeed be caused by a large number of compound–
protein interactions; a recent study by Flachner et al. [63] 
found a total of ∼300 proteins to be targeted by com-
pounds cytotoxic in cancerous cells (265 molecules) as 
well as healthy cells (251 molecules).
As can be seen in Supplementary Table S1, high fre-
quency of prediction does not always correspond to a 
high enrichment (see also Supplementary Information, 
Enrichment methods comparison), thereby under-
lining the importance of normalizing predictions to 
a background distribution to eliminate biases in the 
chemical space, as well as the models, to the extent 
possible. Overall, 48% of the targets predicted for at 
least 5% of the compounds (i.e., targets whose absolute 
frequency of prediction is higher than 47) were found 
to be not enriched (data not shown). On the other 
hand, 37% of the enriched targets were predicted for at 
least 5% of the compounds. Two extreme cases are rep-
resented by the proteins thymidylate synthase (TYMS) 
and carbonic anhydrase 6 (CA6). For the former the 
Estimation Score equals 0 (indicating significance) 
while the absolute frequency encountered in the data-
set is only 5 (see Supplementary Table S1); whereas 
for the latter the Estimation Score equals 1 while the 
absolute frequency of prediction is as high as 116.
The top enriched targets (defined in the further 
analysis as those proteins whose Estimation Score is 
equal to 0), are listed in Table 1 along with literature 
links to cytotoxic phenotype. The most enriched tar-
get is NAD(P)H dehydrogenase [quinone] 1 (NQO1, 
Average Ratio = 0.0052). NQO1 is an enzyme that 
catalyzes the two-electron reduction of quinones to 
hydroquinones. The cytotoxic activity of the hydro-
quinones is exploited in cancer therapy, where a num-
ber of side effects can be observed because of cytotox-
icity in healthy tissue [64]. The Multidrug resistance 
protein 1 (ABCB1, Average Ratio = 0.0818), also 
known as P-Glycoprotein (PGP), is also important in 
tumor treatment. ABCB1 is a transmembrane protein 
responsible for xenobiotics efflux, whose overexpres-
sion causes multi-drug resistance (MDR) in response 
to chemotherapeutic treatment [65]. Moreover, impli-
cation of ABCB1 in cytotoxicity was also proven in 
the study combining in silico bioactivity profiling and 
in vitro measurements from which the library analyzed 
in this work was extracted [46].
A substantial number of phosphorylating proteins 
(kinases and phosphatases) were found to be enriched. 
Protein kinases are enzymes whose role consists of 
adding a phosphate group to other proteins in order 
to regulate their activity. More than 500 kinases are 
found in the human genome [77], and their broad 
expression, together with their implication in a large 
number of cellular processes, renders them an impor-
tant family of drug targets in several conditions. An 
important example is cancer [78], where kinase inhibi-
tors often exert their activity through cytotoxicity. 
More specifically, modulation of serine/threonine-
protein kinase Chk1 (CHEK1, most enriched kinase, 
Average Ratio = 0.0384) and Wee1-like protein kinase 
(WEE1, Average Ratio = 0.0743) both alone and syn-
ergistically was recently found to be important in 
blocking neuroblastoma cell growth [69]. Similarly, 
the cytotoxic effect responsible for the activity of sev-
eral anticancer agents has been shown to be linked to 
inhibition of tyrosine–protein kinase JAK1 (JAK1, 
Average Ratio = 0.0801) [73] and activation of proto-
oncogene tyrosine–protein kinase Src (SRC, Average 
Ratio = 0.0881) [76], whereas the role played by tyro-
sine-protein kinase Lck (LCK, Average Ratio = 0.0536) 
in apoptosis modulation [70] could be responsible for 
the anticancer activity of natural compounds [71]. 
Hence, these targets show a clear connection with the 
cytotoxicity phenotype.
A second group of enriched targets comprises 
proteins related to DNA regulation, which is essen-
tial for cell replication and cell death, and accordingly 
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the proteins contained in this class are in many cases 
current targets in cancer therapy. The most enriched 
targets in this cluster are Histone deacetylase 8 and 10 
(HDAC8 and HDAC10, whose Average Ratio equals 
0.0138 and 0.0240, respectively): given the impor-
tance of HDACs in cell cycle and apoptosis regula-
tion, HDAC inhibitors have therapeutic application in 
cancer treatment. [66] Interference with the processes 
of mRNA translation as well as DNA replication 
and repair are responsible for the cytotoxic activity 
of TYMS (Average Ratio = 0.0594) inhibitors [72] and 
DNA topoisomerase 1 (TOP1, Average Ratio = 0.0832) 
inhibitors. [74] As for the previously discussed ABCB1, 
TOP1 is implicated in cytotoxicity as recently observed 
by Cortes-Ciriano et al. [46]. Hence, also in this second 
MoA cluster clear links between enriched targets and 
the cytotoxic phenotype could be established.
The importance of both kinase activity and DNA 
modulation in cytotoxicity was recently demon-
strated by combining in silico and in vitro screenings 
to discriminate between cytotoxicity in cancer and 
healthy cells [63]. In particular, 52% of the cancer 
selective proteins were kinases, and SRC was found 
to be one of the most enriched proteins from this 
group. Moreover, 21% of the enriched proteins played 
an important role in transcription regulation, with 
several members of the histone deacetylase family 
found to be enriched. Even though the dataset used 
in our analysis was derived from a different source, 
the results are consistent with the above study, thus 
Table 1. The top enriched targets for the cytotoxicity dataset are listed along with Average Ratio and literature links 
to the phenotype.
Target Average Ratio Implication in cytotoxicity Ref.
NAD(P)H dehydrogenase 
[quinone] 1 (NQO1)
0.0052 Enzyme that catalyzes the two-electron reduction of quinones 
to hydroquinones, whose cytotoxic activity is exploited in cancer 
therapy
[64]
Histone deacetylase 8 (HDAC8) 0.0138 Important in cell cycle and apoptosis regulation. HDAC inhibitors are 
used in cancer treatment
[66]
 Histone deacetylase 10 (HDAC10) 0.0240
Vasopressin V1b receptor 
(AVPR1B)
0.0250 AVPR1B plays a proinflammatory role in the gastrointestinal tract, 
and antagonists of this receptor are able to prevent induced cellular 
damage
[67]
Telomerase reverse 
transcriptase (TERT)
0.0372 TERT is fundamental in preserving the telomere length. It is implicated 
in apoptosis, transcription, metabolic reprogramming, etc
[68]
Serine/threonine-protein kinase 
Chk1 (CHEK1)
0.0384 Modulation of CHEK1 important in blocking neuroblastoma cell 
growth
[69]
Tyrosine-protein kinase Lck 
(LCK)
0.0536 LCK plays an important role in apoptosis modulation which could be 
responsible for the anticancer activity of natural compounds
[70,71]
Thymidylate synthase (TYMS) 0.0594 TYMS inhibitors are used in cancer therapy given their toxicity 
caused by interference with mRNA translation and DNA replication
[72]
Wee1-like protein kinase (WEE1) 0.0743 Modulation of WEE1 important in blocking neuroblastoma cell 
growth
[69]
Tyrosine-protein kinase JAK1 
(JAK1)
0.0801 Inhibition of JAK1 is responsible for the cytotoxic effect caused by 
several anticancer agents
[73]
Multi-drug resistance protein 1 
(ABCB1)
0.0818 Transmembrane protein responsible for xenobiotics efflux, whose 
overexpression causes multi-drug resistance (MDR) in response to 
chemotherapeutic treatment
[65]
DNA topoisomerase 1 (TOP1) 0.0832 TOP1 inhibitors interfere with mRNA translation and DNA 
replication. Implication in cytotoxicity was recently proven in a study 
combining in silico and in vitro measurements
[46,74]
P2X purinoceptor 7 (P2RX7) 0.0864 Expressed on the cellular membrane of inflammatory cells, where they 
interact with extracellular ATP and mediate a number of responses 
including cytotoxicity. It is upregulated in a number of tumors
[75]
Proto-oncogene tyrosine-
protein kinase Src (SRC)
0.0881 Activation of SRC is responsible for the cytotoxic effect caused by 
several anticancer agents
[76]
All the targets present Estimation Score = 0, hence they are ranked according to their Average Ratio values. All the most enriched targets found a clear link with the 
cytotoxicity phenotype.
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supporting the importance of the targets obtained in 
cytotoxicity.
Overall, the top enriched targets from all three 
groups have explicit literature links with the cytotoxic 
phenotype, confirming the validity of the methodol-
ogy. In the following we will now compare our analysis 
of targets to the analysis of annotated pathways.
Pathways analysis
The predicted targets were annotated with pathways 
extracted from KEGG, GO and GO Slim, and the 
annotated pathways were subjected to enrichment 
calculation (see Materials & Methods for details). A 
total of 77 out of 171 KEGG pathways were found to 
be enriched, and for 59 of those the Estimation Score 
equals 0 (Supplementary Table S2). Regarding GO 
Slim biological processes, 62 out of 167 were found 
to be enriched, for 54 of which the Estimation Score 
equals 0 (Supplementary Table S3). Finally, 1071 out 
of 2565 GO biological processes were found enriched, 
863 of which with an Estimation Score of 0 (see 
Supplementary Table S4). As already observed for tar-
gets, a high number of enriched terms is due to both 
size of the dataset and multiple MoA of the molecules 
contained in it [63]. Moreover, also in this case a high 
frequency of annotation for a pathway does not always 
correspond to a high enrichment value. Taking into 
consideration the KEGG pathways whose frequency of 
annotation falls in the top 5% (i.e., whose frequency of 
annotation is higher than 157), 56% are enriched (data 
not shown). On the other hand, only for 71% of the 
enriched KEGG pathways the absolute frequency of 
annotation is in the highest 5%, so also some pathways 
relatively rare in absolute numbers can be significant 
when compared with the background distribution. An 
example of an enriched KEGG pathway with a low 
annotation frequency is ‘hsa00531 glycosaminogly-
can degradation’ (Estimation Score = 0, frequency of 
annotation = 10, see Supplementary Table S2), whereas 
the pathway ‘hsa04080 Neuroactive ligand–receptor 
interaction’ presents both high Estimation Score (1) and 
frequency of annotation (3147, data not shown). Simi-
lar situations are found also for the GO and GO Slim 
annotation, confirming the importance of the enrich-
ment calculation to normalize prediction frequencies 
with regard to a background distribution.
The enriched pathways and biological processes 
from all ontologies (KEGG, GO and GO Slim) will 
in the following be discussed jointly, given the consid-
erable overlap that exists between them. In all cases, 
the enriched pathways were found to be implicated 
in similar and strongly correlated processes, namely, 
cancer, immune response, DNA replication and repair 
and mitosis. In order to focus on the most significant 
pathways from here on only pathways whose Estima-
tion Score equals 0 will be included in the analysis 
(and pathways are further sorted by the Average Ratio 
measure, see Materials & Methods for details).
The biggest group identified comprises pathways 
important in cancer development and/or immune 
response (Table 2), and because of the established link 
between dysfunction of immunity and carcinogenic-
ity [79] the two classes will here be considered together. 
Inside this group, several overlaps between annotations 
coming from the three sources used can be noticed, 
such as the enriched KEGG pathway ‘hsa02010 ABC 
transporters’ (Average Ratio = 0.1851), as well as the two 
enriched, yet more general, GO Slim biological pro-
cess ‘GO:0051181 cofactor transport’ (Average Ratio 
= 0.0864) and ‘GO:0015893 drug transport’ (Average 
Ratio = 0.1166). These entries are lined to processes such 
as cell detoxification as well as MDR [80] in which the 
enriched target PGP takes part. Similarly, a subcluster 
comprising processes important in the activity modula-
tion of Natural Killer cells (NK) can be identified. In 
particular, the ‘hsa04640 Hematopoietic cell lineage’ 
(Average Ratio = 0.3520) is a process that starts from 
hematopoietic stem cell to give several blood cell types, 
including NK cells [81]. On the other hand, impaired 
NK function is responsible for ‘hsa05340 primary 
immunodeficiency’ (Average Ratio = 0.2153), a condi-
tion characterized by increased predisposition to infec-
tions, autoimmune diseases and cancer [82]. Finally the 
KEGG pathway ‘hsa04520 Adherens junction’ (Average 
Ratio = 0.3691) and their components ‘hsa04514 Cell 
adhesion molecules (CAMs)’ (Average Ratio = 0.3658) 
all regulate NK function. Nectin, a CAM, is a ligand 
for the immunoglobulin superfamily of receptors: these 
receptors are expressed on the outer membrane of NK, 
and by interacting with nectin modulate the functions 
of these cells, known to be importantly correlated to 
pathogenic and tumorigenic responses [83]. As the name 
suggests, NK cells exert cytotoxic activity on infected, 
neoplastic or other immune cells [82], thus enrichment 
of this subcluster of processes regulating their activity 
fits into the studied phenotype.
The second cluster of pathways, as for targets, 
is composed of pathways related to DNA and cell 
cycle (Table 3), and has some general exponents in 
the GO Slim terms ‘GO:0006259 DNA metabolic 
process’ (Average Ratio = 0.3956). A strong cor-
relation is observed because of their fundamental 
role played on DNA repair for the general GO Slim 
entry ‘GO:0006281 DNA repair’ (enriched for both 
GO and GO Slim annotation, with an Average Ratio 
of 0.3026 and 0.3009, respectively), the two KEGG 
pathways ‘hsa00562 inositol phosphate metabolism’ 
and ‘hsa03450 Nonhomologous end-joining’ (whose 
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Average Ratio equals 0.1698 and 0.1175, respectively), as 
well as the GO counterpart of the latter ‘GO:0010569 
regulation of double-strand break repair via homolo-
gous recombination’ (Average Ratio = 0.0384). As 
nonhomologous and homologous end joining are two 
fundamental processes of DNA repair following dou-
ble-strand breaks [91], they are important in cytotox-
icity caused by agents damaging DNA. On the other 
Table 2. The most enriched KEGG pathways, GO and GO Slim biological processes related to cancer and immune 
response. 
Enriched pathways and 
biological processes
Average 
Ratio
Cancer and immune response Ref.
KEGG
hsa00531 Glycosaminoglycan 
degradation
0.1435 Glycosaminoglycans are targeted by anticancer drugs. They induce 
cytotoxicity by binding soluble proteins to form amyloid plaques
[84,85]
hsa02010 ABC transporters 0.1851 Linked to processes such as cell detoxification as well as multidrug 
resistance (MDR)
[80]
hsa05100 Bacterial invasion of 
epithelial cells
0.1872 The biological processes triggered by pathogens involve the same 
pathways implicated in autoimmunity. The process is thus compatible 
with the cytotoxicity phenotype
 
hsa04330 Notch signaling 
pathway
0.2064 Dysfunctions of this pathway play an important role in the pathogenesis 
of several rumors. It is responsible for the cytotoxic effects of 
γ-secretase inhibitors, originally designed against Alzheimer’s and 
furthermore been exploited to target various forms of cancer
[86]
hsa05340 Primary 
immunodeficiency
0.2153 Condition characterized by increased predisposition to infections, 
autoimmune diseases and cancer
[82]
hsa04630 Jak-STAT signaling 
pathway
0.2262 Implicated in both autoimmunity and canceroggenity. The enriched 
member of this pathway JAK1 mediates cytotoxicity after inhibition by 
anticancer agent
[73, 
87–88]
hsa04640 Hematopoietic cell 
lineage
0.3520 Process that starts from hematopoietic stem cell to give several blood 
cell types, including NK cells
[81]
hsa04514 Cell adhesion 
molecules (CAMs)
0.3658 CAMs, in particular nectin, modulate the pathogenic and tumorigenic 
responses mediated by NK cells 
[83]
hsa04520 Adherens junction 0.3691  
hsa04660 T cell receptor 
signaling pathway
0.6824 The role of T cells is fundamental in the immune response and their 
relation to cytotoxic activity has been established previously
[89,90]
GO Slim
GO:0051181 cofactor transport 0.0864 Linked to processes such as cell detoxification as well as multi-drug 
resistance (MDR) 
[80]
GO:0015893 drug transport 0.1166  
GO
GO:0050862 positive regulation 
of T cell receptor signaling 
pathway
0.0536 The role of T cells is fundamental in the immune response and their 
relation to cytotoxic activity has been established previously
[89,90]
GO:0006027 glycosaminoglycan 
catabolic process
0.1435 Glycosaminoglycans are targeted by anticancer drugs. They induce 
cytotoxicity by binding soluble proteins to form amyloid plaques 
[84,85]
GO:0030203 glycosaminoglycan 
metabolic process
0.1536  
GO:0007219 Notch signaling 
pathway
0.2017 Dysfunctions of this pathway play an important role in the pathogenesis 
of several rumors. It is responsible for the cytotoxic effects of 
γ-secretase inhibitors, originally designed against Alzheimer’s and 
furthermore been exploited to target various forms of cancer
[86]
All the pathways and biological processes in this table present Estimation Score = 0, hence they are ranked according to their Average Ratio values. Given the 
fundamental role played by these processes in life of cells, they have a clear link with the cytotoxicity phenotype.
GO: Gene Ontology; NK: Natural Killer.
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hand, the role of the inositol phosphate metabolic path-
way in cytotoxicity is related to both DNA repair and 
immune-mediated cytotoxicity. For the former, the ter-
minal product inositol hexaphosphate (IP6, polyphos-
phorylated carbohydrate) is important in activating the 
Non-homologous end-joining pathway, while the lat-
ter consists in activation of NK cells cytolytic activity 
by the intermediate inositol-1,4,5-trisphosphate (IP3) 
[92]. A second sub-group is represented by the strongly 
interconnected processes ‘GO:0006333 chromatin 
Table 3. The most enriched KEGG pathways, GO and GO Slim biological processes related to DNA regulation and cell 
cycle are listed along with their Average Ratio values and the biological function they mediate. 
Enriched pathways and biological 
processes
Average 
Ratio
DNA regulation and cell cycle Ref.
KEGG
hsa03450 Nonhomologous end-joining 0.1175 Fundamental process of DNA repair following double-strand 
breaks; important in cytotoxicity caused by agents damaging DNA
[91]
hsa00562 Inositol phosphate metabolism 0.1698 The terminal product of this pathway inositol hexaphosphate 
(IP6) is important in activating the Nonhomologous end-joining 
pathway, whereas the intermediate inositol-1,4,5-trisphosphate 
(IP3) activates NK cells cytolytic activity
[92]
GO Slim
GO:0016458 gene silencing 0.1870 Process that regulates genes expression  
GO:0007059 chromosome segregation 0.2689 Process taking place during DNA replication and in mitosis [94]
GO:0006397 mRNA processing 0.2918 Process taking place during transcription  
GO:0006281 DNA repair 0.3009 Process taking place after DNA damage  
GO:0006259 DNA metabolic process 0.3956 Any metabolic process involving DNA  
GO
GO:0006333 chromatin assembly or 
disassembly
0.0138 Chromatin function is fundamental in DNA transcription [93]
GO:0022616 DNA strand elongation 0.0372 Telomeres play a fundamental role in DNA replication; 
alteration of these processes might cause a number of diseases 
as well as cancer 
[68,95]
GO:0007004 telomere maintenance via 
telomerase
0.0372  
GO:0032203 telomere formation via 
telomerase
0.0372  
GO:0045839 negative regulation of 
mitosis
0.0384 Process that stops cellular division  
GO:0010569 regulation of double-
strand break repair via homologous 
recombination
0.0384 Fundamental process of DNA repair following double-
strand breaks, important in cytotoxicity caused by agents 
damaging DNA
[91]
GO:0046602 regulation of mitotic 
centrosome separation
0.0384 Centrosome plays an important role in mitosis [96]
GO:0010767 regulation of transcription 
from RNA polymerase II promoter in 
response to UV-induced DNA damage
0.0384 Important in preventing the apoptotic processes triggered by 
UV-induced DNA damage
[97]
GO:2000615 regulation of histone H3-K9 
acetylation
0.0384 Histone function is important in cell cycle and DNA transcription [93]
GO:0035407 histone H3-T11 
phosphorylation
0.0384  
GO:0007059 chromosome segregation 0.0832 Process taking place during DNA replication and in mitosis [94]
GO:0006281 DNA repair 0.3026 Process taking place after DNA damage  
All the pathways and biological processes inthis table present Estimation Score = 0, hence they are ranked according to their Average Ratio values. Given the 
fundamental role played by these processes in life/death balance of cells, they have a clear link with the cytotoxicity phenotype. 
GO: Gene Ontology; NK: Natural Killer; UV: Ultraviolet.
Figure 3. A large number of targets enriched for the cytotoxicity dataset are members of the kinase protein family, a class of 
proteins implicated in a number of biological processes. All the enriched KEGG pathways annotated with the enriched kinases were 
collected in order to identify the role of kinases in the cytotoxicity phenotype. In this way, it was possible to observe how three strictly 
correlated functions are mediated, namely, immune response, cell cycle and cancer (see main text for details). In this representation, 
only the top 20 enriched targets and KEGG pathways are shown, for the complete list please refer to Supplementary Tables S1 & S2.
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assembly or disassembly’ (Average Ratio = 0.0138), 
‘GO:2000615 regulation of histone H3-K9 acetylation’ 
(Average Ratio = 0.0384) and ‘GO:0035407 histone 
H3-T11 phosphorylation’ (Average Ratio = 0.0379), 
which can be considered as part of this group given the 
implication of histone modifications and chromatin 
function in DNA transcription [93].
Given the fundamental role played by these pro-
cesses in the life of cells, there is also a clear link to the 
cytotoxicity phenotype being analyzed here.
As discussed in the previous section, kinases are 
implicated in a vast number of processes fundamental 
to cell health maintenance, thus extrapolating their pre-
cise action on the cytotoxicity phenotype is not trivial. 
For this reason, an explicit comparison was performed 
between the 50 enriched proteins belonging to the 
kinases class and their annotated 91 KEGG pathways 
(see Figure 3 for a schematic representation). The 58 
enriched KEGG pathways annotated with the enriched 
kinases mediate the previously discussed functions, 
namely, immune response, cancer and cell cycle. Hence, 
analysis of the enriched pathways allows easier interpre-
tation of the data as a number of pathways merge into 
the few principal biological functions whose regulation 
is important for the studied phenotype. 
To further investigate the validity of the enrich-
ment calculation, an analysis of the KEGG pathways 
annotated with targets whose Estimation Score equals 
1 was performed. Overall, it was found that the 74 
non-enriched targets were annotated with a total of 
94 KEGG pathways. However, a diverse pathway 
profile was observed for this subset of targets, since 
only two pathways were present with a relatively 
high frequency value (namely, ‘hsa04080 neuroac-
tive ligand–receptor interaction’, whose frequency 
equals 31, and ‘hsa04020 calcium signaling pathway’, 
whose frequency equals 17). It is also remarkable that 
between the 10 most frequently annotated pathways 
for this subset (shown in Supplementary Table S5), 
only one is enriched also for the cytotoxicity dataset, 
namely the ‘hsa05200 Pathways in cancer’. However, 
it is annotated only with four of the non-enriched 
targets, which makes it an underrepresented pathway 
for the subset analyzed. Hence, none of the enriched 
KEGG pathways is significantly represented among 
the non-enriched targets, lending credibility that the 
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enrichment of large number of pathways is unlikely to 
be the case by chance alone.
To compare our results to existing literature (which 
did not involve any in silico target predictions), most of it 
was found to be in agreement with a previously reported 
study integrating a set of proteins known to be targeted 
by protoxins (responsible for cellular damage through 
necrosis and/or apoptosis), their partners in protein–
protein interactions and the pathways these proteins are 
involved in [35]. Analysis of the pathways annotated with 
the 171 proteins directly targeted by protoxins revealed 
38 GO biological processes and 15 KEGG pathways 
to be enriched. The number of enriched terms signifi-
cantly decreased when considering proteins adducted 
by reactive metabolites of at least three protoxins and 
their direct partners (186 targets in total), with three 
GO processes and eight KEGG pathways significantly 
enriched. Although these numbers might seem consid-
erably lower than the results obtained here (where we 
have found 1071 GO processes and 77 KEGG path-
ways to be enriched), a numerical comparison cannot be 
performed since neither the complete list nor the total 
number of annotated terms was released by Fang et al. 
[35]. Moreover, several differences in the methodologies 
(such as different enrichment calculation and cutoff 
used) might be responsible for the numerically diver-
gent results. Furthermore, none of the most represen-
tatives entries (namely, ‘GO:0006457 protein folding’, 
‘GO:0006915 apoptotic process’, ‘hsa04612 Antigen 
processing and presentation’, ‘hsa04010 MAPK signal-
ing pathway’) in this previous study has been obtained 
in our analysis. Nevertheless, several links between 
both analyses can also be identified. In particular, the 
term ‘GO:0006915 apoptotic process’ is equivalent to 
the KEGG term ‘hsa04210 apoptosis’ (Average Ratio = 
0.6449, Estimation Score = 0). The fact that the GO 
term referring to apoptosis was not enriched in our 
analysis might seem surprising given its obvious rela-
tionship with the cytotoxicity phenotype. However, it 
is a demonstration of the importance of merging several 
pathway data sources given the incomplete information 
contained in the available ones [28–29,53–57]. Moreover, 
‘hsa04612 antigen processing and presentation’ can be 
linked to the enriched immune regulation processes 
previously discussed. Finally, ‘hsa04010 MAPK signal-
ing pathway’ is a sub-process of ‘hsa05200 pathways in 
cancer’, and can be considered in the same category of 
the previously discussed pathways implicated in tumor 
modulation. Thus, in spite of the different nature and 
MoA of protoxins compared with the molecules in 
our dataset, the most significantly enriched pathways 
belong to the same categories. This fact emphasizes the 
importance of these processes in the life/death balance 
of cells, as well as further validating our results.
Visualization of distance in structure, target & 
pathway space between cytotoxic & random sets
In this part of the study we aimed to understand whether 
pathway annotations, together with enrichment calcula-
tion, are able to perform a meaningful mapping of pre-
dicted targets onto pathways, in order to allow an easier 
analysis of the biological processes involved. To address 
this, 100 datasets of the same size of the cytotoxicity 
set were randomly selected from the background distri-
bution and processed with the computational pipeline 
involving target prediction, pathway annotation and 
enrichment calculation. Binary (Figure 4) and distance 
(Figure 5) matrices were generated for the test set as well 
as for one of the randomly selected datasets, in order 
to analyze similarities in chemical structure, target 
and pathway space, and understand whether annota-
tion with biological pathways adds any information 
compared with the classic in silico bioactivity profiling 
where only protein targets are taken into account. In 
both heatmaps generated from the studied phenotype 
(Figure 4A & Figure 5A) it is possible to observe how the 
size of clusters increases when moving from structure 
space to target space, and finally to pathway space. In 
particular, in the cytotoxicity compound-fingerprint 
binary matrix (Figure 4A, left-hand side), the clusters 
are very sparse and small, as the biggest cluster in the 
bottom left contains only 7% of the compounds in the 
dataset and 1.9% of the fingerprint features. In the com-
pound-target matrix (Figure 4A, center) a higher degree 
of clustering is observed, with the biggest cluster (center-
left) comprising 5% of the compounds and 3% of the 
predicted targets. In the compound-KEGG pathway 
binary matrix (Figure 4A, right-hand side) the situation is 
different again, where the largest cluster in the top-right 
corner contains 41% of the annotated pathways as well 
as 48% of the compounds. However, a similar behavior 
of clustering is observed also in the heatmaps obtained 
for the random dataset (Figure 4B). While no noticeable 
clustering is observed for the random compound-finger-
print binary matrix (Figure 4B, left), the number and 
dimension of clusters increases in target and pathway 
space. In particular, a big cluster is noticeable on the 
left-hand side of the random compound-target binary 
matrix (Figure 4B, center), which comprises 7% of the 
predicted targets and 19% of the compounds. Similarly, 
the cluster on the top right of the random compound-
KEGG heatmap (Figure 4B, right) comprises 48% of 
both compounds and KEGG pathways. Consider-
ing the heatmaps representing distance between com-
pounds in structure space, a similar increase in number 
of clusters is observed moving from structure to path-
ways. Moreover, a different profile between cytotoxic 
(Figure 5A, left) and random (Figure 5B, left) compounds 
is noticeable, which indicates both a moderate structural 
Figure 4. Heatmap representations of binary matrices of cytotoxic compounds. Fingerprints (left), predicted 
protein targets (center) and annotated KEGG pathways (right) for: (A) the cytotoxicity dataset, compared with 
(B), a random dataset. For every compound, a light green cell indicates presence of the feature, whereas a black 
cell indicates absence of the feature. The number of clusters in increases moving from the left (fingerprints) to the 
right (KEGG pathways), as a result of the decreasing number of features describing the compounds. Hence, this 
indicates that interpretability of mechanism of action is increased by annotating targets with pathways.
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similarity among cytotoxic compounds and a success-
ful sampling of diverse molecules in the random set. 
This could be further explained by analyzing the total 
number of fingerprint features annotated with the 
two sets, the frequency of annotation/prediction of 
these frequency, and the mean and standard deviation 
among them (Table 4). For cytotoxic compounds, the 
total number of fingerprint features (1881) is consid-
erably lower than for the random set (3018), whereas 
the opposite is observed for maximum frequency (474 
for cytotoxicity and 179 for random set) and standard 
deviation (26.97 for cytotoxicity and 6.79 for random 
set). The higher maximum frequency and lower num-
ber of fingerprint features observed for the cytotoxic set 
indicates a higher similarity among compounds (since 
more compounds share the same chemical features). On 
the other hand, the lower values of maximum frequency 
and standard deviation observed in the random set indi-
cate diversity among compounds, since few compounds 
share the same substructures.
A higher degree of similarity between cytotoxic 
molecules (Figure 5A) and between random molecules 
(Figure 5B) is observed also in target (Figure 5A, center) 
and pathway (Figure 5A, right) space. However, the 
number of clusters increases when moving from struc-
ture to target to pathway space also in the random set. 
Although a bigger difference between random and 
cytotoxic profiles would be expected, it is important 
to remember that given the dimension of the dataset 
and the multiple MoA responsible for the cytotoxicity 
phenotype (as discussed in section 2.1), the total num-
ber of predicted targets and annotated pathways will 
not differ significantly from what observed in random 
sets (Table 4). Moreover, compounds are described 
in domains very different in dimension: whereas the 
number of fingerprint features representing the mol-
ecules in the datasets is in the order of thousands, the 
number of features decreases considerably when con-
sidering targets (a maximum of 477 targets can be 
predicted) and KEGG pathways (a maximum of 176 
pathways can be annotated to targets). Hence, the 
multiple MoAs and the different domains of features 
used to describe compounds appear to be responsible 
for the partly similar profiles observed in the cytotoxic 
and random sets. Further analysis on a set of molecules 
sharing a more specific mode of action, as well as an 
Figure 5. Heatmap representations of distance matrices between cytotoxic compounds. Fingerprints (left), protein 
targets (center) and KEGG pathways (right) for: (A) the cytotoxicity dataset, compared with (B) a random dataset. 
For every compound the darker the cell, the more similar the compounds are. The number of clusters, as well as 
their dimension, increases moving from the left (fingerprints) to the right (KEGG pathways). This is particularly 
evident in (A), whereas a smaller degree of clustering is observed in (B). This finding indicates that the information 
added by pathway annotation is important in order to group compounds having a similar phenotypic readout.
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increased number of members in the protein and path-
way spaces (which is unfortunately not available at the 
moment) would help with clarifying this. Nonetheless, 
the increasing number of clusters observed in pathway 
space suggests a mapping of multiple targets (as well 
as multiple compounds) onto the same pathway (con-
firmed in most of the cases for enriched pathways and 
biological processes, see Supplementary Figures S1 & S2), 
hence attesting the help provided by the annotation 
step in facilitating the analysis of the results.
The validity of our approach on a phenotypic dataset 
can be further confirmed by considering the number of 
enriched items for the 100 random sets, which was sig-
nificantly lower than in the cytotoxicity set. In particu-
lar, the maximum number of enriched items in a ran-
dom set was 12 protein targets, 17 KEGG pathways, 
Table 4. The total number of fingerprint features, targets and KEGG pathways predicted/annotated 
with the cytotoxicity and random datasets.
Dataset Feature No of features Minimum 
frequency
Maximum 
frequency
Mean Standard deviation
Cytotoxicity Fingerprints 1881 1 474 10.73 26.97
 Targets 400 1 297 36.81 44.69
 Pathways 171 1 3147 378.38 447.77
Random Fingerprints 3018 1 179 3.33 6.79
 Targets 388 1 503 47.99 87.11
 Pathways 168 1 6332 384.13 677.89
Figure 6. The bar plot shows the number of enriched items for the cytotoxicity dataset and the average number 
of enriched items for the random sets along with the standard deviation in each class (targets, KEGG, GO and 
GO Slim) and the outliers. The number of enriched items in the cytotoxicity dataset is considerably higher than in 
the random sets, confirming a non-casual enrichment for the cytotoxicity set.
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68 GO biological processes and 12 GO Slim biologi-
cal processes, against 151 targets, 77 KEGG path-
ways, 1071 GO biological processes and 62 GO Slim 
found to be enriched in the cytotoxicity set (Figure 6). 
Moreover, none of these items results particularly over-
enriched (Supplementary Figure S3). Hence, this dem-
onstrates how the high number of enriched items for 
the cytotoxicity dataset does not happen by chance.
Overall, our initial hypothesis that pathway annota-
tion together with enrichment calculations adds infor-
mation to the MoA elucidation of a set of compounds, 
compared with target prediction alone, has been con-
firmed here by showing a better mapping of predicted 
targets onto annotated pathways and a non-casual 
enrichment for the cytotoxicity set.
However, it should also be noted that the analysis per-
formed here depends on the size of dataset studied, as we 
will also outline in more detail in the following section.
Apoptosis dataset
Ten compounds (see Table 5 for the list of compounds 
along with their biological properties) were selected 
because of their ability to induce apoptosis. The dataset 
was subjected to the computational pipeline described 
in Materials & Methods, yielding 108 unique predicted 
targets and 109 KEGG, 135 GO Slim and 1180 GO 
unique annotated processes. Given the diverse bioactiv-
ity profiles of the molecules in the apoptotic dataset, 
together with its small dimension, the enrichment cal-
culations did not lead to statistically significant results. 
This will be discussed in the following sections, together 
with the analysis of the most frequently predicted targets 
and most frequently annotated pathways. Moreover, for 
each compound the targets and pathways predicted and 
annotated will be considered individually.
Target analysis
The enrichment calculation gave rise to a limited num-
ber of enriched targets (shown in Table 6), with only 
four proteins (3.7% of the predicted targets) being 
enriched. This value is particularly low when com-
pared with the cytotoxicity dataset, where 37.8% of the 
predicted targets were found enriched. Moreover, the 
enriched targets are not representative of the dataset, 
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given that only one was predicted for three compounds, 
while the remaining three were only predicted for an 
individual compound from the set. Similar results 
were also obtained for pathways analysis (see follow-
ing section), making an enrichment-based analysis on 
this small dataset difficult. An analysis of the most 
frequently predicted targets in absolute terms does not 
lead to more successful results either: the most recur-
rent target was predicted four times, while frequency 
for the subsequent seven targets equals three, for the 
following 21 targets it equals two and finally for the 
last 79 targets it equals only one (see Table 6 for the top 
10 most predicted targets). This observation, together 
with the lack of significant clusters in the compound-
fingerprint and compound-target heatmaps (shown in 
Figure 7), highlights the multiple and diverse bioactiv-
ity profiles of the molecules in the dataset as well as 
our need for an additional individual analysis of links 
between compounds and their MoAs.
The ten targets most frequently predicted in abso-
lute terms were subjected to literature search to 
understand whether they might still be implicated in 
apoptotic mechanisms (Table 7). As already observed 
in the cytotoxicity case study, it is possible to cluster 
targets according to their bioactivity. In particular, 
seven out of the 10 protein targets are neurotrans-
mitter receptors, namely α-2 adrenergic receptors 
(ADRA2A, ADRA2B and ADRA2C), D3 dopa-
mine receptor (DRD3), 5-hydroxytryptamine recep-
tor 2B (HTR2B), muscarinic acetylcholine receptors 
(CHRM1 and CHRM2). ADRA2C is the most pre-
dicted receptor (with a frequency of prediction equal 
to 4), followed by the other two members of the same 
family ADRA2B and ADRA2C (three predictions in 
both cases). Implication of ADRA receptors in apop-
totic mechanisms is indeed supported by literature: Bri-
monidine, an ADRA2 agonist, has a protective action 
against apoptosis induced by glutamate and H
2
O
2
 
in spiral ganglion neurons, which can be reversed by 
the ADRA2 antagonist yohimbine [113]. On the other 
hand, yohimbine has been associated with protection 
from myocardial apoptosis in mice presenting cardiac 
dysfunction through multiple mechanisms involving 
inhibition of ADRA2 [114]. Although these two pieces 
of evidences might seem contrasting, the different 
tissues in which the measurements were carried out 
Table 5. The compounds in the apoptotic dataset are listed along with their main use and their implication in apoptosis.
Compound Activity Implication in apoptosis Ref.
Quinacrine Antimalarial drug Suppression of nuclear factor-kappa B (NFKB1) and activation of p53 
(TP53) signaling
[98]
Perhexiline Antianginal agent Mitochondrial protection from oxidative stress caused by fatty acids 
loading; interaction with Serine/threonine-protein kinase mTOR
[99,100]
Hycanthone Antiparasitic, 
intercalating agent
Inhibition of DNA-(apurinic or apyrimidinic site) lyase (APEX1) [101]
Puromycin Antibiotic Increases caspase 3-mediated apoptosis [102]
Ellipticine Antineoplastic 
agent
Inhibition of RNA polymerase I (POL-I), suppression of TOP2, 
apoptosis promotion through both caspase-dependent and caspase-
independent mechanisms
[103,104]
Benzethonium chloride Antiseptic drug Able to cause apoptosis in stem cells but not fibroblasts, increase of 
cytosolic Ca2+ in erythrocytes
[45,105]
Mefloquine Antimalarial agent Neurotoxicity associated with apoptosis mediated through 
activation of Non-receptor tyrosine-protein kinase TYK2, induces 
apoptosis in breast cancer
[106,107]
Ursolic acid Natural product 
used in food and 
cosmetic industry
Disruption of the anti-apoptotic Glucose-6-phosphate isomerase 
(PGI) signaling pathway in hepatoma cells, apoptosis induced in 
colon cancer cells through multiple apoptotic pathways modulation
[108,109]
Tetrandrine Calcium-channel 
blocker
Caspase activation, reactive oxygen species (ROS) production, 
modulation of RAC serine/threonine-protein kinase (AKT) pathway, 
and inhibition of mitochondrial antiapoptosis proteins
[110]
Cycloheximide Inhibitor of protein 
biosynthesis 
in eukaryotic 
organisms
Involvement of c-Jun N-terminal kinases (JNKs) and caspase 
activation in apoptosis induced by combination of Rumor necrosis 
factor-α (TNF) and cycloheximide, down regulation of FLIP (CASP8 
and FADD-like apoptosis regulator, CFLAR) in human fat cells
[111,112]
From the literature links between the compounds and apoptosis it is possible to notice the diverse MoA spectrum of the dataset. 
MoA: Mechanism of action.
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(neurons in the former, myocardial cells in the latter) 
seem to play a role, and in both cases they show a type 
of involvement of the ADRA2 receptor in apoptosis. 
Importance in apoptotic modulation is recognized also 
for the cholinergic [115], serotoninergic [116] dopaminer-
gic [117] receptors frequently predicted (please refer to 
Table 7 for details). Similarly, links to apoptosis were 
found also for the final three protein targets belong-
ing to the top 10 most predicted, namely, testosterone 
17-β-dehydrogenase 3 (HSD17B3, two predictions in 
the dataset) [118], potassium voltage-gated channel sub-
family H member 2 (KCNH2, three predictions) [119] 
and the Serine/threonine-protein kinase pim-2 (PIM2, 
two predictions) (Table 7) [120].
Hence, all the top 10 predicted targets found litera-
ture links with apoptosis. However, none of these tar-
gets found a literature annotation with the processes 
responsible for the apoptotic response mediated by the 
compounds in the dataset. This finding should not 
necessarily be interpreted as a failure of prediction, but 
instead it confirms the importance of in silico bioactiv-
ity profiling methods in filling in the gaps in the knowl-
edge of the full bioactivity spectrum of molecules, and 
in suggesting MoA hypotheses in addition to the ones 
already known. In this particular case, target predic-
tion contributes to the MoA analysis by suggesting 
novel targets that could contribute to the apoptotic 
response triggered by the compounds in the dataset.
Individual analysis of the non-frequent targets pre-
dicted for each compound was performed to understand 
whether the predicted targets overlap with the experimen-
tally annotated ones. However, also here only a limited 
number of MAP kinases, important in apoptotic pro-
cesses [123], were predicted for few compounds, namely, 
ellipticine, cycloheximide, hycanthone and quinacrine 
(data not shown). This result highlights the common 
limitation of in silico bioactivity profiling methodologies 
that rely on ligand–protein interaction data (see [16] for 
a recent overview of the field). In this context, consid-
eration of the annotated pathways appears even more 
important in helping to elucidate MoAs, and this is what 
we will describe in the following section.
Pathway analysis
A similar situation to the one described for targets 
was found also in case of the pathways analysis. 
No KEGG pathways presented an Estimation Score 
higher than the usual cutoff of 0.01, whereas only 
two GO Slim and 19 GO biological processes were 
enriched (Supplementary Table S6). This trend is dif-
ferent from that observed in the cytotoxicity analysis, 
where 45% of the annotated KEGG pathways, 37% 
Table 6. Enriched and ten most frequently predicted targets for the apoptosis dataset. 
Targets Frequency Average Ratio Estimation Score Odds Ratio
Enriched targets
Equilibrative nucleoside transporter 1 1 0.0057 0.0057 231.6807
Inosine-5’-monophosphate dehydrogenase 1 1 0.0076 0.0076 177.1676
Dopamine D3 receptor 3 0.1558 0.0076 8.8219
C-C chemokine receptor type 4 1 0.0086 0.0086 158.5184
Top 10 predicted targets     
α-2c adrenergic receptor 4 0.3985 0.0605 3.4800
Dopamine D3 receptor 3 0.1558 0.0076 8.8219
Potassium voltage-gated channel subfamily H 
member 2
3 0.1857 0.0158 7.5993
α-2a adrenergic receptor 3 0.4032 0.1068 3.4376
α-2b adrenergic receptor 3 0.5732 0.2389 2.4103
Serotonin 2b (5-HT2b) receptor 3 0.8509 0.4904 1.6355
Muscarinic acetylcholine receptor M2 3 1.4715 0.8968 0.9449
Muscarinic acetylcholine receptor M1 3 1.5083 0.9063 0.9211
Serine/threonine-protein kinase PIM2 2 0.0868 0.0143 16.2510
Testosterone 17-β-dehydrogenase 3 2 0.0903 0.0127 15.5651
Enriched targets are ranked according firstly to their Estimation Score values, and secondly to their Average Ratio values, whereas the top 
10 targets are ranked according firstly to their frequency of prediction, and secondly to their Odds Ratio value. The frequency of prediction 
of the enriched targets has a low absolute value in every case, indicating that the enriched targets on the apoptotic dataset cannot be 
considered representative. While the 10 targets most frequently predicted in absolute terms also have a low frequency of prediction, they 
still cover more compounds and could also be linked to the phenotype in a literature analysis. This illustrates that depending on the size and 
nature of the dataset a different mechanism of action analysis needs to be performed.
Figure 7. Heatmap representations of matrices between apoptotic compounds based on their fingerprints (left), 
protein targets (center) and KEGG pathways (right). (A) Binary matrix, every compound in the a light green cell 
indicates presence of the feature, whereas a black cell indicates absence of the feature. (B) Distance matrix, the 
darker the cell, the more similar the compounds are. In both (A) and (B) the number of clusters increases upon 
moving from left (fingerprints) to right (KEGG pathways). The clusters in the target heatmaps are smaller than 
those in the KEGG heatmaps, highlighting the multiple bioactivity profiles of the molecules in the dataset. This 
finding confirms the importance of pathway annotation in emphasizing the processes whose modulation by the 
molecules in the dataset leads to a given biological outcome, overcoming the limitation given by the diverse 
mechanism of action of the molecules in the dataset. 
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of the annotated GO Slim biological processes and 
42% of the annotated GO biological processes were 
found enriched (compared with 0, 1.5 and 1.6% for 
the apoptosis phenotype, respectively). Furthermore, 
the enriched items are not always representative of 
the dataset, since low absolute frequencies of anno-
tation are recorded. The frequency of annotation 
equals six for the enriched GO Slim biological process 
‘GO:0050879 multicellular organismal movement’, 
while it equals only one for ‘GO:0015931 nucleo-
base-containing compound transport’. The situation 
is slightly different for the GO annotations, where 
19 terms are enriched; however, their frequency val-
ues span from one to four only, which is as sparse as 
in case of the enriched targets and GO Slim terms. 
On the other hand, the absolute frequency of annota-
tion for KEGG (Supplementary Table S7), GO Slim 
(Supplementary Table S8) and GO (Supplementary Table S9) 
are considerably higher than those recorded for targets, 
given that a large number of targets merge into fewer 
but highly populated pathways. However, the high 
frequency of annotation observed for pathways and 
biological processes is influenced not only by fre-
quent targets, but also from targets predicted only 
once which map onto the same pathway. An example 
is the entry ‘hsa04080 neuroactive ligand–receptor 
interaction’, whose absolute frequency of annotation 
is equal to 56 and is annotated to 35 predicted targets 
(Supplementary Table S7). However, only 13 of the 
annotated targets were predicted for more than one 
compound in the dataset (data not shown). Hence, 
the absolute frequency of annotation is also not ideal 
in representing important pathways for the apop-
totic dataset. Nonetheless, it is possible to observe a 
bigger clustering in the compound-KEGG than in 
the compound-fingerprint and compound-target dis-
tance matrices (Figure 7), demonstrating similarity 
between compounds in pathways space. This suggests 
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Table 7. The ten most frequently predicted targets for the apoptosis dataset along with their implication in 
apoptosis, which was supported by literature for all the protein targets.
Target Link to apoptosis Ref.
α-2c adrenergic receptor Implication of adrenergic receptors in apoptotic mechanisms 
is supported by literature. In particular, ADRA2 agonist has a 
protective action against apoptosis in spiral ganglion neurons, 
whereas ADRA2 antagonist have been associated with 
protection from myocardial apoptosis
[113,114]
α-2a adrenergic receptor  
α-2b adrenergic receptor  
Dopamine D3 receptor DRD3 mediates the protective response to serum deprivation 
in peripheral nerve sheath rumor (MPNST) cells through the 
inhibition of neurofibromatosis type 1 (NF1, proapoptotic) 
gene expression
[117]
Serotonin 2b (5-HT2b) receptor Selective antagonism of HTR2B was recently found to cause 
apoptosis in fibrogenic hepatic stellate cells
[116]
Muscarinic acetylcholine receptor M2 Cholinergic receptors are implicated in apoptotic modulation. 
In particular, agonism of CHRM2 was shown to block tumor 
growth through activation of apoptotic mechanisms
[115,121]
Muscarinic acetylcholine receptor M1  
Potassium voltage-gated channel subfamily H 
member 2
KCNH2 is known to be expressed in a number of cancer cells 
where it controls cell proliferation and apoptosis
[119]
Serine/threonine-protein kinase PIM2 PIM2 is up-regulated in many cancer types (both solid and 
hematological), where it exerts antiapoptotic regulation
[120]
Testosterone 17-β-dehydrogenase 3 HSD17B3 is an enzyme fundamental for the synthesis of 
androgens and estrogens, hormones that play a role in 
modulating pathways implicated in cell viability and rumor 
cells growth. Inhibitors of this enzyme are being exploited as 
cancer therapies given their ability to block rumor growth in 
several types of cancer by an apoptotic mechanism
[118,122]
that pathway annotations are useful to gain improved 
insight into the MoAs underlying phenotypic readouts 
of the apoptotic set, as already observed in the case 
of cytotoxicity. Hence, only the pathways and biologi-
cal processes annotated with at least two of the top 10 
targets will be considered for further (Table 8).
As already observed for the cytotoxicity case study, 
the most frequent items coming from different data 
sources can be grouped into multiple related processes. 
More precisely, a number of processes implicated in 
ligand–receptor interaction are often annotated with 
the most frequent targets, namely, the two KEGG 
annotations ‘hsa04080 neuroactive ligand–receptor 
interaction’ (annotated to seven targets) and ‘hsa04725 
cholinergic synapse’ (two annotations), the GO terms 
‘GO:0007186 G-protein-coupled receptor signaling 
pathway’ (seven annotations), ‘GO:0071875 adren-
ergic receptor signaling pathway’ (three annotations), 
‘GO:0032811 negative regulation of epinephrine secre-
tion’ (three annotations), ‘GO:0010700 negative regu-
lation of norepinephrine secretion’ (three annotations) 
and finally the term ‘GO:0007165 signal transduction’ 
observed for both GO and GO Slim annotation 
(eight annotations in both cases). The KEGG entry 
‘hsa04080 neuroactive ligand–receptor interaction’ 
is not a standard pathway, but rather a collection of 
neuroactive ligands and the receptors with which they 
interact. However, its high frequency of annotation 
among frequent targets, and the similarly high fre-
quency of annotation of other processes linked to the 
ligand–receptor interaction, highlights the activation 
of neurotransmitters signaling caused by the molecules 
in the apoptotic dataset already observed with the 
targets analysis (as discussed in the previous section).
On the other hand, several terms annotated with 
the most frequent targets can be directly correlated to 
apoptosis through literature, such as the KEGG pathway 
‘hsa04020 calcium signaling pathway’ (three annota-
tions). Ca2+ is a secondary messenger that regulates a 
plethora of cellular functions, including apoptotic pro-
cesses through activation of caspases [142]. Not surpris-
ingly, given the important role played by caspases in 
apoptosis regulation, their activation has been observed 
for most of the compounds in the dataset, namely, quin-
acrine [98], puromycin [102], ellipticine [103], mefloquine 
[106], ursolic acid [108], tetrandrine [110], cycloheximide 
[111] and benzethonium chloride [45]. Similarly, several fre-
quent pathways and biological processes could be related 
to the bioactivity of a number of compounds in the 
dataset (please refer to Table 8 for a detailed discussion).
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Table 8. The most frequent KEGG pathways, GO and GO Slim biological processes annotated with the subset of top 
10 predicted targets.
Pathways and biological processes Frequency Link to apoptosis Ref.
KEGG
hsa04080 Neuroactive ligand–
receptor interaction
7 Apoptosis is regulated by the predicted targets mapping to 
this pathway, namely ADRA2, CHRM1 and CHRM2, HTR2B and 
DRD3
[113–117, 
121]
hsa04020 Calcium signaling pathway 3 Ca2+ mediated-apoptosis through activation of caspases 
has been observed for quinacrine, puromycin, ellipticine, 
mefloquine, ursolic acid, tetrandrine, cycloheximide and 
benzethonium chloride
[45,98, 
102–103, 
106,108, 
110–111]
hsa04725 Cholinergic synapse 2 Cholinergic receptors are important in apoptosis mediation in 
cancer cells
[115,121]
hsa04810 Regulation of actin 
cytoskeleton
2 The actin cytoskeleton is involved in apoptosis. Its regulation 
is mediated by NADPH oxidase, which can be modulated by 
perhexiline and puromycin. Moreover, benzethonium chloride 
and ursolic acid affect cytoskeleton stability
[124–129]
GO
GO:0007165 signal transduction 8 Biological processes linked to the frequently predicted 
receptors modulating apoptosis
 
GO:0007186 G-protein-coupled 
receptor signaling pathway
7  
GO:0008284 positive regulation of 
cell proliferation
4 Any process that activates cell proliferation  
GO:0071883 activation of MAPK 
activity by adrenergic receptor 
signaling pathway
3 MAPK signaling is important in apoptotic processes, and can 
be modulated by cycloheximide as well as ursolic acid pathway
[35,130–131]
GO:0071875 adrenergic receptor 
signaling pathway
3 Linked to the apoptotic activity mediated by the frequently 
predicted adrenergic receptors
[113,114]
GO:0044281 small molecule 
metabolic process
3 Process activated by xenobiotics in general, thus expected to 
be frequently annotated
 
GO:0035625 EGFR transactivation by 
G-protein-coupled receptor signaling 
pathway
3 EGFR regulates apoptosis, and disruption of its pathway is 
responsible for cancer. Quinacrine resistance was observed 
after activation of EGFR, whereas ellipticine and EGF exhibited 
a synergistic effect in causing growth inhibition of EGFR-
overexpressing breast cancer. Moreover, modulation of EGFR 
could contribute to the activity of ursolic acid and tetrandrine
[131–135]
GO:0032148 activation of protein 
kinase B activity
3 Protein kinase B promotes cell survival by inhibiting apoptotic 
signaling. Quinacrine, mefloquine, ursolic acid and tetrandrine 
antiproliferative activity on tumor cells is mediated by 
modulation of the protein kinase B pathway
[135–139]
GO:0010700 negative regulation of 
norepinephrine secretion
3 Linked to the apoptotic activity mediated by the frequently 
predicted adrenergic receptors
[113,114]
GO:0032811 negative regulation of 
epinephrine secretion
3  
GO Slim
GO:0032501 multicellular organismal 
process
9 The high frequency of this process derives from misannotation 
in the data source
 
GO:0065007 biological regulation 9 Generic term indicating any process that modulates a 
biological function
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Overall, analysis of the pathways has allowed us to elu-
cidate the MoA of the apoptotic compounds in the data-
set in an improved way than considering targets alone. 
Although the most frequently predicted targets do not 
represent the experimentally annotated proteins targeted 
by the molecules in the dataset, they have an implica-
tion in apoptosis, thus representing a novel hypothesis 
on the apoptotic MoA of the compounds. Moreover, the 
pathways annotated to the most frequent targets reflect 
the biological mechanisms responsible for the apoptotic 
response to the compounds in the dataset. Furthermore, 
the larger clusters observable in both KEGG binary and 
distance matrices compared with fingerprints and tar-
gets (Figure 7) confirm the importance of pathway anno-
tation: they demonstrate similarity between compounds 
in pathways space, thus highlight the processes whose 
modulation leads to a given biological outcome, apop-
tosis in this case. This allows us to overcome the limita-
tion of targets analysis alone, which are caused by the 
multiple MoA of the molecules in the dataset.
Apart from improving the MoA analysis itself, it 
should be noted that our pathway annotation approach 
also permitted us to notice a misannotation in the GO 
database. More specifically, the GO Slim biological 
process ‘GO:0032501 multicellular organismal pro-
cess’, according to the version of GO Slim used here, 
is annotated with the predicted protein targets β-2 
adrenergic receptor (ADRB2), Ribosomal protein S6 
kinase β-1 (RPS6KB1) and D-3 dopamine receptor 
(DRD3). However, in the current version (checked 
online on 17 June 2014) annotation of these proteins 
with the aforementioned biological process is not pres-
ent, reflecting the incomplete information contained 
in biological data sources as well as their evolving 
nature [28–29,53–57].
Conclusion
As shown in this study, the annotation of predicted 
targets with pathways can give new insights into 
understanding the MoA of drugs, underlining path-
ways implicated in the studied phenotype which would 
not have been detected by only considering the pre-
dicted protein targets. This has been evaluated on two 
datasets, namely, a large cytoxicity dataset, as well as 
a considerably smaller dataset comprising compounds 
which elicit an apoptotic response in cells. In the cyto-
toxicity case study, enrichment calculations of signifi-
cant targets were found to be fundamental in eliminat-
ing biases in the targets predicted. In the second step, 
pathway annotations lead to an improved understand-
ing of the different pathways that might be implicated 
in the phenotype. Hence, target prediction increases 
interpretability for the readouts analyzed here, but even 
more so the subsequent pathway annotations com-
bined with enrichment calculation, as shown by the 
comparison of results with random sets. On the other 
hand, the analysis performed on the apoptotic dataset 
highlighted that analyses on small datasets need to be 
performed differently than on larger datasets, and that 
an analysis of absolute numbers of predicted targets 
seems to be more appropriate. It is also important to 
specify that this methodology aims to help the MoA 
Pathways and biological processes Frequency Link to apoptosis Ref.
GO:0007165 signal transduction 8 Cellular process deriving from reception of a signal which 
regulates a downstream cellular process. Can be linked to 
GPCRs activity, and hence to the predicted receptors
 
GO:0048856 anatomical structure 
development
7 Generic term indicating the development of any anatomical 
structure, which includes apoptotic processes involved in 
development
 
GO:0007267 cell–cell signaling 5 Alteration of cell–cell signaling can lead to apoptosis [140]
GO:0050896 response to stimulus 5 General term indicating cellular response to an external 
stimulus
 
GO:0030154 cell differentiation 4 Proteins and pathways implicated in apoptosis are proven to 
be important in activating the cell differentiation process
[141]
GO:0044281 small molecule 
metabolic process
4 Process activated by xenobiotics in general, thus expected to 
be frequently annotated
 
GO:0009987 cellular process 4 General term referring to any process happening at the 
cellular level
 
GO:0006468 protein phosphorylation 4 Protein kinases modulates a plethora of functions, hence they 
are fundamental in cell life
[78]
Table 8. The most frequent KEGG pathways, GO and GO Slim biological processes annotated with the subset of top 
10 predicted targets (cont.).
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elucidation of a set of molecules causing a known phe-
notypic response. For example, the KEGG pathway 
‘hsa04020 calcium signaling pathway’ was found to 
be the second most annotated pathway for the apop-
totic dataset, and indeed its importance in regulating 
apoptotic processes is well known [142]. However, an 
interpretation of this finding such as ‘every compound 
interacting with the calcium signaling pathway has an 
apoptotic activity’ would not be valid, since the final 
cellular effect depends on which step (protein) of the 
pathway is modulated and the way it is modulated 
(activation or inhibition, for instance; as well as other 
factors such as concentration of the compound, etc.). 
Finally, we have been able to identify inconsistencies 
in GO annotations (which was corrected in a more 
recent version) when looking into the most frequently 
annotated biological processes for the apoptotic data-
set, underlining the importance of using reliable data 
for biological analyses.
Overall, we were able to show that pathway anno-
tations, together with enrichment calculation, add 
value to in silico MoA analyses of phenotypic datas-
ets. Although the two datasets were very different in 
nature, the added information regarding pathways 
improved interpretability of the data in both cases. 
However, statistical significance of the enrichment 
methodology was proven only for the larger cytotoxic-
ity dataset, illustrating the need to adapt the analysis 
performed to the specific case studied. This is likely to 
be the case generally when trying to deconvolute tar-
gets from phenotypic screening using in silico target 
prediction algorithms.
Future perspective
The development of computational power is likely to 
make in silico bioactivity analyses even more accessible 
and easier to perform in the future. At the same time, 
data sources containing information about the bioac-
tivity of compounds are increasing in size at a high 
speed. Thus, the combination of both factors is very 
likely to lead to quantitatively and qualitatively better 
in silico MoA analyses of phenotypic endpoints.
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Executive summary
•	 We evaluated the annotation of pathways onto in silico target predictions on two different datasets with very 
different characteristics – a cytotoxicity dataset containing more than 1000 members and a apoptosis dataset 
which only comprised 10 compounds.
•	 We have found that the integration of compound structures, protein targets modulated, as well as pathway 
information gives a better understanding of the mechanism of action of a compound than using activities 
against protein targets alone.
•	 Pathways also show significantly more clustering than compound structure similarities, or target/bioactivity 
profile similarities, hence facilitating the analysis of subclusters which cause the same phenotype, but via 
different mechanisms of action.
•	 The analysis performed needs to be tailored to the particular phenotypic dataset, as clearly demonstrated when 
describing the differences between the cytotoxic and apoptotic endpoints considered in the current study.
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